Additionally, numerous studies have demonstrated that pretreatment serum albumin is a significant prognostic marker for tumors, with low serum albumin levels being strongly associated with poor outcomes in cancer patients (Chen et al., 2016; Liu and Wang, 2020; Guven et al., 2022). The gene discussed is ALB; the disease is cancer.